Physician profile
Jose Polanco
NPI 1043854961
$5,506.61
in general payments reported to CMS, 2019-2025
32 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 92% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $484 · 2022: $745 · 2023: $1,152 · 2024: $1,370 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,277.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,114.56 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $815.57 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $666.93 | 2025 | Rezdiffra |
| Abbvie INC. | $476.12 | 2021-2023 | |
| Novo Nordisk INC | $431.68 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $389.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $361.37 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $310.89 | 2021-2023 | Korlym |
| Ardelyx, INC. | $164.44 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $114.96 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Exact Sciences Corporation | $110.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.68 | 2021-2025 | Jardiance |
| Pfizer INC. | $50.32 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $44.77 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $43.43 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $41.50 | 2023 | Situate |
| Otsuka America Pharmaceutical, INC. | $37.21 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $34.91 | 2025 | Arexvy, Shingrix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $29.46 | 2021 | |
| Jazz Pharmaceuticals INC. | $28.83 | 2022 | |
| Globus Medical, INC. | $19.66 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $17.63 | 2025 | |
| Mannkind Corporation | $15.92 | 2025 | |
| Amgen INC. | $15.69 | 2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $15.57 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $15.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.06 | 2022 | |
| Bausch Health US, LLC | $13.84 | 2022 | |
| Horizon Therapeutics Plc | $11.76 | 2022 | |
| Intuity Medical INC | $11.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Polanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.